Engineered antibody Fc variants with enhanced effector function. - Wikidata - thesis-toulmin - TriplyDB

Engineered antibody Fc variants with enhanced effector function.

Engineered antibody Fc variants with enhanced effector function.

http://www.wikidata.org/entity/Q34424958

about

Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies Design of protein-ligand binding based on the molecular-mechanics energy model Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies Engineered IgG1-Fc--one fragment to bind them all Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases A perspective on the structure and receptor binding properties of immunoglobulin G Fc Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells Translating basic mechanisms of IgG effector activity into next generation cancer therapies Tetraspanins as therapeutic targets in hematological malignancy: a concise review Targeting the Fc receptor in autoimmune disease Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development Collective dynamics differentiates functional divergence in protein evolution B Cell-Based Seamless Engineering of Antibody Fc Domains Outcome of a workshop on applications of protein models in biomedical research Advances in Antibody Design Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.Computational approaches for rational design of proteins with novel functionalities CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.Direct prediction of profiles of sequences compatible with a protein structure by neural networks with fragment-based local and energy-based nonlocal profiles Achievements and Challenges in Computational Protein Design.Modern Technologies for Creating Synthetic Antibodies for Clinical application.Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.The importance of human FcgammaRI in mediating protection to malaria.Identification of cyclic peptides able to mimic the functional epitope of IgG1-Fc for human Fc gammaRI.Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells.Progress towards recombinant anti-infective antibodies.Next generation of antibody therapy for cancer.Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions Trastuzumab emtansine: mechanisms of action and drug resistance Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity Monoclonal antibodies: versatile platforms for cancer immunotherapy.Discovery of internalizing antibodies to tumor antigens from phage libraries.

P2860

Q21131216-A936AC02-9E89-4833-81E2-2079CD261E5F Q24651388-1917F71D-A08A-4FE1-A1C1-1F5F880EE9B9 Q26752558-2ACF7D02-CFFD-4DD7-AE0A-9DA45F48146B Q26766715-15E55A62-90E6-4EA4-A536-ECC8814EA04D Q26783175-819BEEBB-18E6-4033-9EBF-0D5FB011F0CF Q26827579-8F95EFFE-3DB3-40EB-BF08-02C67B039550 Q26852287-526C5AA4-0A93-4070-B01E-9F16EEEEDA4F Q26991899-AD95F212-ED68-42B3-A062-2481A54B09EC Q27002353-E792B08B-61AA-46EA-875E-45CB673C1606 Q27002843-49E4DACA-51F9-4D93-AFDE-B121E9D54D08 Q28068946-A096A2A9-B6A8-41B2-94B6-68133B3FCFA9 Q28079016-9C5DDE80-18E5-4E7C-A726-623B238C0BC9 Q28084276-3C850BBE-4D26-4231-AF86-067808BDD476 Q28481742-FD7DC07B-D232-4858-B2C0-C7367082F077 Q28554659-FB47D3AC-4224-4B5B-9826-15A0F029524B Q28751701-B226FBF6-C776-484F-9296-CA5B6A35B8AC Q28817608-0B089EB2-9F76-4BE8-B76E-B9C1783189C1 Q30276243-68165591-6B7A-4EBB-BC9C-1CF5DB9628F8 Q30360853-21045E1B-C474-405B-8033-CF5FB3855F05 Q30360904-7302CD14-13E6-4205-A28B-48B26403E0FD Q30363288-5ADD4980-4CCA-4D9A-AFC3-2016E8B4B058 Q30395939-497F0405-6F4E-47E1-B913-28532EE18908 Q30467308-B0F4821A-7777-47F8-88C5-2CF360E6AE37 Q31083322-1A905924-7DB3-4255-8ADD-F606310B82F7 Q33285037-0D709AD8-4A68-4842-B933-F9D2932C9A99 Q33380014-48BC6FEB-60A9-4180-B9B2-B3EA335D578B Q33410392-B12FA5E4-EBC7-48CE-B4A7-737F0C6C9F75 Q33418091-1383E288-5F1E-4159-8D64-5D8C8F18C84D Q33524710-51A739BA-192D-4029-91DF-4889A3769155 Q33568256-922730BD-63F8-4F21-A5B9-6E4F953565D2 Q33579636-0C2CFAF9-70FE-486C-8366-DE82C842CBBD Q33607045-F97F63A6-20F0-48E9-BAF8-779F6F5ED6BF Q33627797-9E3AB8A3-E1AE-4E4D-9E0E-B0B220B25921 Q33677456-7C941D5C-0758-4EBD-B69A-CE840314EEE3 Q33733443-FE0E43CE-6BC9-4283-A855-A4AFBB795D6F Q33759627-0AD85792-B34B-4F10-83B2-C88ECD5D7B30 Q33766970-248EAA53-CBD7-4A63-B00A-04B079195A78 Q33969383-9376BE17-2C07-4DB3-A35C-F4CCE65EE0D0 Q34111693-8108F176-4ED3-4C9E-9E60-9B6FCA960C5E Q34114794-95EE0184-FB7C-4E9B-993A-8DA18165EA04

P2860

Engineered antibody Fc variants with enhanced effector function.

http://www.wikidata.org/entity/Q34424958

description

2006 nî lūn-bûn

@nan

2006 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մարտին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Engineered antibody Fc variants with enhanced effector function.

@ast

Engineered antibody Fc variants with enhanced effector function.

@en

Engineered antibody Fc variants with enhanced effector function.

@nl

type

label

Engineered antibody Fc variants with enhanced effector function.

@ast

Engineered antibody Fc variants with enhanced effector function.

@en

Engineered antibody Fc variants with enhanced effector function.

@nl

prefLabel

Engineered antibody Fc variants with enhanced effector function.

@ast

Engineered antibody Fc variants with enhanced effector function.

@en

Engineered antibody Fc variants with enhanced effector function.

@nl

P1433

Q34424958-4CFBC37C-A9E4-4B52-B90C-99C58C51A2DD

P1476

Q34424958-F739F865-9093-4844-BFA0-0B902A561BEF

P2093

Q34424958-17B9664B-4E4E-4F84-B8B6-0923D3CF9EA4

Q34424958-1D363DD0-B549-42C1-B77F-30156944BE18

Q34424958-22DFF0B3-7C5B-4D2E-A13B-DD682E5A8118

Q34424958-3404B437-B951-435C-A588-BA1AD82B8296

Q34424958-371ED210-2967-455C-95AC-C50CDD9AEA58

Q34424958-54D02323-13B2-4F6A-A944-82EEBA718905

Q34424958-605A735E-F56B-401E-90FE-19B37125789B

Q34424958-7442D852-AA3E-4D55-8847-413D137B4FE4

Q34424958-76BBA183-1601-4733-9590-209F507F2EF2

Q34424958-7BB8BDCE-1087-4536-B0BA-2C21E94BA739

P2860

Q34424958-072272AA-5C13-47BD-98AC-00149F692B65

Q34424958-0FDF17A8-BC62-49A2-A195-B26CE61DBE31

Q34424958-186E8E4A-0BA7-4BEC-8607-AAA1198170B4

Q34424958-1AEF97F4-A901-42A2-A806-D82E1BD479D3

Q34424958-2112BB8F-B36E-4BA2-881C-F1B9810F6DEF

Q34424958-2DC1CAA3-B145-4BB8-9A6F-A9EB9EA37840

Q34424958-3050A1B1-FBE0-41E6-A3E4-22E5AFC89C2F

Q34424958-319E162C-E7F9-4668-8D50-D8676AC615E1

Q34424958-36CFC400-91B4-43E0-B88D-72A3FB70DF01

Q34424958-47F7407B-92F4-4F9C-817C-7C55068D3998

P304

Q34424958-60400B29-564D-4871-B048-8829A1598DB8

P31

Q34424958-555BD417-46D2-402C-8228-E96BD8BAA91D

P356

Q34424958-F01DF04D-320A-4E32-AA8E-C043A948F8DC

P407

Q34424958-7DCCB8FD-7232-45C8-AB13-966927950A6A

P433

Q34424958-6652D7F5-2001-4E91-8274-C5F127A5CEE0

P478

Q34424958-A94483A5-E99A-4003-ADB7-0559E9EA041F

P577

Q34424958-6C77AA38-30FF-4342-902C-4DD99DC288DF

P5875

Q34424958-EF483A21-4473-473E-95AD-2321AD4A5D84

P698

Q34424958-2FDC3F19-DE5A-4444-A6FA-1084E7F5A6EC

P921

Q34424958-7BF201C5-6C21-45C8-A0F3-845823CE5951

P932

Q34424958-4BDE7324-59D8-48C3-8BFF-2FA9F5087DF2

P356

PNAS.0508123103

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Engineered antibody Fc variants with enhanced effector function.

@en

P2093

Araz Eivazi

http://www.w3.org/2001/XMLSchema#string

Bassil I Dahiyat

http://www.w3.org/2001/XMLSchema#string

Cheryl Chan

http://www.w3.org/2001/XMLSchema#string

David F Carmichael

http://www.w3.org/2001/XMLSchema#string

Greg A Lazar

http://www.w3.org/2001/XMLSchema#string

Helen S Chung

http://www.w3.org/2001/XMLSchema#string

Jost Vielmetter

http://www.w3.org/2001/XMLSchema#string

Judy S Peng

http://www.w3.org/2001/XMLSchema#string

Linus Hyun

http://www.w3.org/2001/XMLSchema#string

Omid Vafa

http://www.w3.org/2001/XMLSchema#string

P2860

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

Molecular basis for immune complex recognition: a comparison of Fc-receptor structures

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Rational design and engineering of therapeutic proteins

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

Fc receptors and their interactions with immunoglobulins

Recognition of immunoglobulins by Fcgamma receptors

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Protein design automation.

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

P304

4005-4010

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0508123103

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2006-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7242028

http://www.w3.org/2001/XMLSchema#string

P698

16537476

http://www.w3.org/2001/XMLSchema#string

P921

P932

1389705

http://www.w3.org/2001/XMLSchema#string